
    
      This is a randomized, double-blind, placebo-controlled, comparative Phase 3, multicenter
      international study to evaluate the efficacy and safety of BA058 (abaloparatide) 80 Âµg in the
      prevention of fracture in otherwise healthy ambulatory postmenopausal women with severe
      osteoporosis.
    
  